论文部分内容阅读
一、麒麟麦酒公司研制的G—CSF制剂GRAN注射剂已经上市。该药是利用遣传因子组合技术生产的并只限于白细胞减少的患者使用。在给药中,应对患者进行定期的血液检查,当白细胞达到正常水平时,应减量或停止给药。临床上适用于:骨髓移植时,可促进白细胞增殖;在癌症化疗时,对白细胞减少症、恶性淋巴肿癌、急性白血病、肺癌、卵巢癌等症有促进白细胞增殖的效果;对再生障碍性贫血伴有白细胞减少症的先天性、特发性白细胞减少也有明显的治疗效果。
First, Kirin ale company developed G-CSF preparation GRAN injection has been listed. The drug is a combination of trojas produced by the technology and is limited to leukopenia patients. During dosing, patients should be given regular blood tests, which should be reduced or stopped when white blood cells reach normal levels. Clinically applicable to: bone marrow transplantation, can promote leukocyte proliferation; in cancer chemotherapy, leukopenia, malignant lymphoma, acute leukemia, lung cancer, ovarian cancer embolism have the effect of promoting leukocyte proliferation; aplastic anemia Congenital leukopenia, idiopathic leukopenia also have a significant therapeutic effect.